①Moderna’s early entry is the strongest endorsement for the “personalized neoantigen tumor vaccine” technology; ②The current bottleneck in the development of neoantigen tumor vaccines no longer lies in delivery or synthesis techniques. What matters truly is how to accurately predict tumor mutations; ③Once it is proven that this product can significantly reduce the risk of postoperative recurrence during adjuvant therapy, the commercial potential of the product will be greatly enhanced.
Moderna’s phase III clinical trial for tumor vaccines achieved significant results, leading to a 177% surge in stock price; its technical approach was endorsed.
The individualized mRNA tumor vaccine Intismeran autogene jointly developed by Moderna and Merck Sharp & Dohme achieved significant results in a key phase III clinical trial targeting high-risk melanoma patients. The study involved 1,137 patients, and the results showed that the combined treatment regimen resulted in statistically significant improvements in the primary endpoint of disease-free survival and the key secondary endpoint of distant metastasis survival compared to the single-drug therapy Keytruda. The safety profile remained consistent with previous findings. This therapy involves synthesizing vaccines using gene sequencing and AI to identify patient-specific neoantigens, with a preparation cycle of approximately 6 weeks. After the announcement, Moderna’s stock price surged by 177% in a single day, with its market value increasing by about 44 billion US dollars. The biopharmaceutical sector in the A-share market and mRNA-related stocks in the Hong Kong stock market also experienced significant increases. This breakthrough is seen as an important clinical endorsement of the “personalized neoantigen tumor vaccine” technology. Industry analysts believe that the current bottleneck in this field has shifted from delivery or synthesis technologies to how to accurately predict tumor mutations. Once it is confirmed that this therapy can be effective during adjuvant treatment…
Moderna’s phase III clinical trial for tumor vaccines achieved significant results, leading to a 177% surge in stock price; its technical approach was endorsed.
Coverage · reports per dayLANGUAGE SPLIT
Coverage mixSOURCE MIX
Chinese media 2English media 1
Entity relations
Integrated timelineUNIFIED TIMELINE
2026-09-04
Moderna’s phase III clinical trial for tumor vaccines was successful, and its technical approach was endorsed.
The individualized mRNA tumor vaccine jointly developed by Moderna and Merck achieved significant results in key phase III clinical trials targeting high-risk melanoma patients. The study involved 1137 patients, and results showed that the combination therapy outperformed Keytruda alone in terms of major endpoints such as recurrence-free survival and key secondary endpoints like distant metastasis…
2 reports
2026-09-05
Moderna’s phase III clinical trial for tumor vaccines was successful, leading to a surge in stock price.
Two scientists predicted a breakthrough in cancer treatment; Moderna’s stock price soared 177%. Revolution Medicines received FDA approval for a prostate cancer drug.
Moderna’s pioneering success is the strongest endorsement for the technology of “personalized neoantigen tumor vaccines”. Currently, the bottleneck in this field has shifted from delivery or synthesis technologies to precise prediction of tumor mutations. Once it is confirmed that this approach can significantly reduce the risk of postoperative recurrence during adjuvant therapy, the commercial potential of this product will increase greatly.
The individualized mRNA tumor vaccine Intismeran autogene (mRNA-4157) jointly developed by Moderna and Merck successfully passed the trials in a key phase III clinical study targeting high-risk melanoma patients. The study involved 1,137 patients, and results showed that the combination therapy achieved statistically significant improvements in both the primary endpoint of disease-free survival and the key secondary endpoint of distant metastasis survival compared to the single-drug therapy Keytruda. The safety profile remained consistent with previous findings. After the announcement, Moderna’s stock price soared by 177% in a single day, with its market value increasing by approximately 44 billion US dollars. The biopharmaceutical sector in the A-share market and mRNA-related stocks in the Hong Kong stock market also experienced significant increases. This breakthrough is regarded as an important clinical endorsement of the “personalized neoantigen tumor vaccine” technology. The preparation period is approximately 6 weeks, and the vaccine is synthesized after identifying patient-specific neoantigens using gene sequencing and AI. Industry analysts believe that the choice of melanoma with strong immunogenicity and the use of a combined immune checkpoint inhibitor strategy are key factors in this success…
Two scientists made a bet on “impossible” cancer therapies and achieved breakthroughs. On August 19, Moderna announced positive results from its melanoma trial, causing its stock price to soar by 177%; on August 26, Revolution Medicines received FDA approval for a molecular “glue” drug for advanced prostate cancer. Although these drugs are not cure methods, they are considered breakthrough options that can target different mutations and train the immune system. Previously, the bankruptcy rate of biotech companies was about two-thirds, but this year there has been an unusually successful trend in this field, with investors reaping huge returns.